Celldex Therapeutics, Inc. may offer common stock, preferred stock, warrants, depositary shares and units from time to time, with specific offering terms and net proceeds to be specified in prospectus supplements.
CLDX · Celldex Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Celldex Therapeutics, Inc. reported that two Phase 3 barzolvolimab studies in CSU met primary and all key secondary endpoints, with 1,939 patients enrolled; it plans to submit a BLA to the FDA in 2027.
Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 met primary and key secondary endpoints, supporting barzolvolimab in CSU, with a BLA submission planned for 2027. Celldex Therapeutics reported $650.3 million in cash, cash equivalents and marketable securities, funding planned operations through 2028.
Celldex reported that barzolvolimab met primary and all key secondary endpoints at 12 weeks in two Phase 3 chronic spontaneous urticaria trials, with favorable safety through 24 weeks and a planned FDA BLA submission in 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients enrolled in EMBARQ-CSU1 and EMBARQ-CSU2 | 1,939 | second quarter ended June 30, 2026 | — |
| Shares outstanding | 78.5M | second quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLDX
this stock
Celldex Therapeutics, Inc.
|
$2.20B | +2.9% | +87.8% | — | 12.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 16
Celldex Therapeutics, Inc. may offer common stock, preferred stock, warrants, depositary shares and units from time to time, with specific offering terms and net proceeds to be specified in prospectus supplements.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLDX | -2.0% | -3.5% | -7.2% | -7.1% | +3.0% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +3.5% | +2.8% | -1.6% | -1.8% | -2.0% |